AML Labs Explained: What Blood and Bone Marrow Tests Reveal After Diagnosis
Join us on Wednesday, August 6, 2025 at 3pm PDT | 6pm EDT (U.S.)
After an AML diagnosis, treatment often begins right away—leaving little time to process what’s happening, let alone what your lab results mean.
In this discussion, AML survivor Steve Buechler speaks with Dr. Alice Mims from The Ohio State University Comprehensive Cancer Center about the key blood and bone marrow tests that guide treatment, track progress, and inform long-term decisions. From CBCs and blast counts to FLT3 and NPM1 mutations, they break down what you need to know moving forward.
Topics:
- Learn what your CBC results mean—including white blood cells, hemoglobin, and platelet counts
- Understand what blast cells are and why they matter in AML
- Hear how bone marrow biopsies and genetic testing (like FLT3 or NPM1) shape your treatment
- Get guidance on monitoring your bloodwork during treatment and remission
- Know when to consider clinical trials and how MRD tracking may guide next steps
Thank you to The Leukemia & Lymphoma Society for their partnership. The Leukemia & Lymphoma Society is here for you with information about clinical trials, resources, and dedicated support through their Information Specialists.
Register for this informative program then invite a Friend or Care Partner.
Whether you’ve just been through induction treatments or have been living with acute myeloid leukemia for years, this conversation is for you.
